LDS/Medical Tests/Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Gene Mutation Analysis (Translocation)

Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Gene Mutation Analysis (Translocation)

The NTRK2 gene, located on chromosome 9q21.33, encodes the neurotrophic receptor tyrosine kinase 2 (TrkB), a high-affinity receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NTF4). This receptor plays a key role in neuronal differentiation, survival, synaptic plasticity, and maintenance of the central and peripheral nervous systems. Upon ligand binding, NTRK2 undergoes autophosphorylation and activates downstream signaling cascades such as the MAPK/ERK, PI3K/AKT, and PLCγ pathways, which are essential for neurogenesis and synaptic maintenance. Pathogenic alterations in NTRK2 are associated with a range of neurodevelopmental, neuropsychiatric, and oncogenic disorders.

In Obesity, Hyperphagia, and Developmental Delay (OBHD) rare neurodevelopmental disorder a biallelic or heterozygous pathogenic variants in NTRK2 result in impaired BDNF-TrkB signaling, leading to early-onset obesity, abnormal appetite regulation, and neurocognitive delays. Some patients may also present with seizures and autonomic dysfunction.

NTRK2 polymorphisms have also been linked to psychiatric conditions, particularly treatment-resistant depression. The rs1565445 T/T genotype has been associated with reduced response to antidepressants and mood stabilizers compared with C/T or C/C variants, suggesting that NTRK2 genetic status may influence neurotrophin-mediated mood regulation.

Additionally, activating rearrangements or translocations involving NTRK2 have been implicated in oncogenesis, notably in pilocytic astrocytoma and other MAPK-driven gliomas, where constitutive receptor activation promotes tumor proliferation. Thus, NTRK2 testing serves both neurodevelopmental and oncologic diagnostic purposes.

  • As an aid in the diagnosis of OBHD and related neurodevelopmental disorders
  • Provides predictive information for antidepressant response and treatment resistance
  • Aids in molecular characterization of astrocytomas and other neural tumors with MAPK pathway activation
  • Helps guide potential targeted therapy decisions involving TRK inhibitors in oncology

Positive Result: Presence of an NTRK2 mutation or translocation consistent with increased susceptibility to neurodevelopmental, psychiatric, or oncologic conditions.

Negative Result: No pathogenic variants or rearrangements detected. However, absence of detectable mutation does not exclude disease; clinical correlation is advised.

Negative (No mutations detected)

Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS) for detection of point mutations, small insertions/deletions, and translocations.

Whole blood, EDTA.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unstable
NTRK1 and NTRK3 mutation analysis, BDNF gene sequencing, Comprehensive neuropathy or neurodevelopmental panel, NGS.
5 to 10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login